Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Intravenous Immunoglobulin (IVIG) Market Forecast to Surge During the Forecast Period (2025-2034) with Rising Demand for Autoimmune and Immunodeficiency Treatments | DelveInsight

      DelveInsight Business Research, LLP Logo

      News provided by

      DelveInsight Business Research, LLP

      May 05, 2025, 17:31 ET

      Share this article

      Share this article


      The intravenous immunoglobulin (IVIG) market is experiencing significant growth due to the rising prevalence of autoimmune diseases, immune deficiencies, and neurological disorders. Advancements in biotechnology and an increased focus on personalized medicine are driving innovation in IVIG therapies.

      LAS VEGAS, May 5, 2025 /PRNewswire/ -- DelveInsight's IVIG Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, emerging IVIG therapy, market share of individual therapies, and current and forecasted IVIG market size from 2020 to 2034, segmented into 7MM [the United States, the EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan].

      Key Takeaways from the IVIG Market Report

      • As per DelveInsight's analysis, the total market size of IVIG in the 7MM is expected to surge significantly by 2034.
      • In 2024, BIVIGAM generated a revenue of approximately USD 50 million in the United States.
      • In 2024, chronic inflammatory demyelinating polyneuropathy affected approximately 21K patients in the United States.
      • Key companies in the market include ADMA Biologics, Grifols Therapeutics, OCTAPHARMA, Takeda Pharmaceuticals, Kedrion Biopharma, LFB Biopharmaceuticals, Biotest, Japan Blood Products Organization, KM Biologics, Teijin, Nihon Pharmaceutical, GC Biopharma, CSL Behring, Pfizer, Evolve Biologics, and others. 
      • Some of the promising IVIG therapies include ASCENIV, BIVIGAM, GAMUNEX-C, OCTAGAM 5% & 10%, GAMMAGARD LIQUID; S/D (immune globulin infusion; Intravenous [human]), GAMMAPLEX 5% & 10%, IQYMUNE, INTRATECT, VENOGLOBULIN, KENKETSU VENILON, Kenketu GLOVENIN-I, YIMMUGO, ALYGLO, PRIVIGEN, PANZYGA, TAK-880, and others.
      • In September 2024, GC Biopharma USA, Inc. announced the launch and distribution of its IG product ALYGLO (IVIG), the company's first 10% IVIG therapy for the treatment of adult patients aged 17 years and older with PI.

      Discover which therapies are expected to grab the IVIG market share @ Intravenous Immunoglobulin Market Report

      IVIG Market Dynamics

      The intravenous immunoglobulin market has seen significant growth over the last few years, driven by a combination of factors, including the increasing incidence of autoimmune and inflammatory disorders, the rising prevalence of immunodeficiencies, and advancements in the development of IVIG therapies. IVIG is used in a variety of indications, from autoimmune diseases like rheumatoid arthritis and lupus to primary and secondary immunodeficiencies. As the global demand for these therapies increases, so does the complexity of the supply chain, with manufacturers needing to ensure that they can meet the growing need for human plasma, a key raw material for IVIG production.

      One of the biggest challenges in the IVIG market is the supply and demand imbalance of human plasma. Plasma collection is a time-intensive process, and the cost of obtaining plasma continues to rise, affecting the overall cost of IVIG production. This leads to fluctuating prices for IVIG, making it a significant concern for both healthcare providers and patients. Additionally, the rising demand for IVIG is outpacing the capacity of plasma donation centers, further exacerbating the supply issue.

      On the other hand, technological advancements in manufacturing processes, such as the development of more efficient purification techniques, have the potential to improve production yields and reduce costs. The growing interest in alternative sources of immunoglobulins, such as recombinant immunoglobulins and synthetic antibodies, also adds a layer of competition to the traditional IVIG market. However, these alternatives are still in the early stages of adoption, with IVIG maintaining its dominant position due to its proven safety and efficacy profile.

      Finally, regulatory and reimbursement policies play a critical role in shaping the IVIG market dynamics. Stringent regulations related to product safety, as well as reimbursement frameworks that vary from region to region, impact market access. Ongoing clinical research into new indications for IVIG, as well as efforts to improve patient outcomes, will be key drivers in shaping the market landscape in the coming years.

      IVIG Treatment Market 

      Multiple VIG products have been approved in the U.S., each tailored to specific clinical needs. These include BIVIGAM, CARIMUNE, FLEBOGAMMA, GAMMAGARD S/D (a low IgA formulation), GAMMAGARD Liquid, GAMMAKED, GAMMAPLEX, GAMUNEX, OCTAGAM, and PRIVIGEN.

      PRIVIGEN is distinguished as one of the rare IVIG therapies approved in all major markets—the US, EU5, and Japan—demonstrating widespread clinical acceptance and strong regulatory endorsement for the treatment of immune deficiencies and autoimmune diseases.

      In recent years, a global shortage of immunoglobulin has become a pressing concern, with Japan notably affected since 2019. The steep increase in demand has necessitated urgent imports. Two major factors driving this demand are the approval of IVIG for halting the progression of chronic inflammatory demyelinating polyneuropathy (CIDP) and the emergence of more concentrated IVIG formulations.

      However, scaling up IVIG production and use poses significant challenges. Chief among them is maintaining a consistent plasma donor supply, a task made even harder during the pandemic due to widespread shutdowns of blood collection facilities. Additionally, IVIG must be administered by trained healthcare professionals in clinical settings, which places added strain on both patients and the healthcare infrastructure.

      Learn more about the approved IVIG therapies @ IVIG Drugs

      Key Emerging IVIG Therapies and Companies

      Several companies—such as Grifols Therapeutics, ADMA Biologics, Takeda, LFB Biopharmaceuticals, OCTAPHARMA, Pfizer, CSL Behring, Biotest AG, and GC Biopharma—are actively involved in the development and commercialization of intravenous immunoglobulin therapies, with many already having approved products established in the market.

      TAK-880, developed by Takeda, is a low IgA-IgG intravenous immunoglobulin formulation under investigation for treating primary immunodeficiency diseases, especially in patients with IgA hypersensitivity. It is currently undergoing regulatory filing with the FDA and EU for approval in this indication.

      The anticipated launch of these emerging therapies are poised to transform the IVIG market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the IVIG market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

      To know more about IVIG clinical trials, visit @ IVIG Therapies 

      IVIG Overview

      Intravenous Immunoglobulin (IVIG) is a blood product derived from the pooled plasma of thousands of healthy donors, containing a broad spectrum of immunoglobulin G (IgG) antibodies. It is primarily used to treat patients with immune deficiencies, autoimmune diseases, and certain inflammatory conditions. In individuals with primary immunodeficiency disorders, IVIG helps provide the necessary antibodies their bodies cannot produce, thereby preventing recurrent infections. Additionally, IVIG plays a vital role in immune modulation, dampening harmful autoimmune responses in diseases like Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy (CIDP), and immune thrombocytopenic purpura (ITP).

      The mechanism of IVIG is complex and multifaceted, involving suppression of pathogenic autoantibodies, modulation of Fc receptors on immune cells, and alteration of cytokine production. Its clinical utility continues to expand, with ongoing research investigating its role in treating conditions like myasthenia gravis, systemic lupus erythematosus, and certain neurological disorders. While generally considered safe, IVIG can cause side effects such as headaches, infusion reactions, and, rarely, thromboembolic events or renal dysfunction, necessitating careful patient selection and monitoring. As a critical therapeutic option in immunology and neurology, IVIG remains a cornerstone for managing diverse immune-mediated disorders.

      IVIG Epidemiology Segmentation

      Primary immunodeficiency diseases had an estimated prevalence of around 38K cases across the EU4 and the UK in 2023. The IVIG market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

      • Total Diagnosed Prevalent Cases of Selected Indications
      • Total Target Patient Pool by Indications
      • Total Treated Patients by Indications

      IVIG Report Metrics

      Details

      Study Period

      2020–2034

      IVIG Report Coverage

      7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]

      Key IVIG Companies

      ADMA Biologics, Grifols Therapeutics, OCTAPHARMA, Takeda Pharmaceuticals, Kedrion Biopharma, LFB Biopharmaceuticals, Biotest, Japan Blood Products Organization, KM Biologics, Teijin, Nihon Pharmaceutical, GC Biopharma, CSL Behring, Pfizer, Evolve Biologics, and others

      Key IVIG Therapies

      ASCENIV, BIVIGAM, GAMUNEX-C, OCTAGAM 5% & 10%, GAMMAGARD LIQUID; S/D (immune globulin infusion; Intravenous [human]), GAMMAPLEX 5% & 10%, IQYMUNE, INTRATECT, VENOGLOBULIN, KENKETSU VENILON, Kenketu GLOVENIN-I, YIMMUGO, ALYGLO, PRIVIGEN, PANZYGA, TAK-880, and others

      Scope of the IVIG Market Report

      • IVIG Therapeutic Assessment: IVIG current marketed and emerging therapies
      • IVIG Market Dynamics: Conjoint Analysis of Emerging IVIG Drugs
      • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
      • Unmet Needs, KOL's views, Analyst's views, IVIG Market Access and Reimbursement

      Discover more about IVIG therapies in development @ IVIG Clinical Trials

      Table of Contents

      1

      Key Insights

      2

      Report Introduction

      3

      IVIG Market Overview at a Glance in the 7MM

      3.1

      Market Share (%) Distribution by Therapies in 2024

      3.2

      Market Share (%) Distribution by Therapies in 2034

      4

      Epidemiology and Market Forecast Methodology

      5

      Executive Summary of IVIG

      6

      Key Events

      7

      IVIG Background and Overview

      7.1

      Introduction

      7.2

      Mechanism of Action

      7.3

      Potential of IVIG

      7.4

      Adverse Reactions to IVIG Therapy

      7.4.1

      Mild to Moderate Immediate Reactions

      7.4.2

      Serious Immediate Reactions

      7.4.3

      Delayed Reactions

      7.4.4

      Preventive Measures and Risk Mitigation

      7.4.5

      Risks and Drawbacks

      7.5

      Current and Emerging IVIG Therapies

      7.6

      IVIG in Different Indications

      7.6.1

      Immune-Mediated Polyneuropathies

      7.6.1.1

      Guillain-Barré Syndrome (GBS)

      7.6.1.2

      Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP)

      7.6.1.3

      Multifocal Motor Neuropathy (MMN)

      7.6.1.4

      Small Fiber Neuropathy (SFN)

      7.6.1.5

      Myasthenia Gravis

      7.6.1.6

      Lambert-Eaton Myasthenic Syndrome (LEMS)

      7.6.1.7

      Stiff-Person Syndrome (SPS)

      7.6.1.8

      Autoimmune Encephalitis and Autoimmune Epilepsy

      7.6.1.9

      Neuromyelitis Optica Spectrum Disorder (NMOSD) and MOG Antibody-Associated Disease (MOGAD)

      7.6.1.10

      Secondary Immunodeficiency Diseases (SIDD)

      7.6.2

      Systemic Immune-Mediated Conditions

      7.6.2.1

      Systemic Vasculitis Syndromes

      7.6.2.2

      Systemic Lupus Erythematosus (SLE)

      7.6.2.3

      Systemic Sclerosis (SSc)

      7.6.2.4

      Inflammatory Myopathies

      7.6.3

      Hematological Disorders

      7.6.3.1

      Immimmune Thrombocytopenia (ITP)

      7.6.3.2

      Immune Thrombocytopenia (ITP)

      7.6.3.3

      Pediatric ITP

      7.6.4

      Pediatric Autoimmune Diseases

      7.6.4.1

      Kawasaki Disease

      7.6.4.2

      Giant Cell Hepatitis with Autoimmune Hemolytic Anemia (GCH with AIHA)

      7.6.4.3

      Fetal and Neonatal Autoimmune and Alloimmune Thrombocytopenia (FNAIT)

      7.6.4.4

      Gestational Alloimmune Liver Disease (GALD)

      7.6.5

      Dermatology

      7.6.5.1

      Bullous Autoimmune Dermatoses

      7.6.5.2

      Stevens-Johnson Syndrome (SJS)

      7.6.6

      SARS-CoV-2 Infection

      7.6.6.1

      Autoimmune Diseases Induced by SARS-CoV-2 Infection

      7.6.6.2

      Long COVID

      8

      Epidemiology and Patient Population

      8.1

      Key Findings

      8.2

      Total diagnosed prevalent cases of selected indications across 7MM

      8.3

      Total Target Patient Pool by indications across 7MM

      8.4

      Total Treated Patients by Indications in the 7MM

      9

      Marketed Therapies

      9.1

      Key cross

      9.2

      ASCENIV (immune globulin intravenous, human–slra): ADMA Biologics

      9.2.1

      Product Description

      9.2.2

      Regulatory Milestones

      9.2.3

      Other Developmental Activities

      9.2.4

      Clinical Development

      9.2.5

      Safety and Efficacy

      9.3

      BIVIGAM (Immune Globulin Intravenous (Human), 10%): ADMA Biologics

      9.3.1

      Product Description

      9.3.2

      Regulatory Milestones

      9.3.3

      Safety and Efficacy

      9.4

      GAMUNEX-C (immune globulin injection (Human), 10%): Grifols Therapeutics

      9.4.1

      Product Description

      9.4.2

      Regulatory Milestones

      9.4.3

      Safety and Efficacy

      9.5

      OCTAGAM 5% & 10%: OCTAPHARMA

      9.5.1

      Product Description

      9.5.2

      Regulatory Milestones

      9.5.3

      Other Developmental Activities

      9.5.4

      Clinical Development

      9.5.5

      Safety and Efficacy

      9.6

      GAMMAGARD LIQUID; S/D (immune globulin infusion; Intravenous [human]): Takeda Pharmaceuticals

      9.6.1

      Product Description

      9.6.2

      Regulatory Milestones

      9.6.3

      Safety and Efficacy

      9.7

      GAMMAPLEX 5% & 10% (Immune Globulin Intravenous (Human), 10%): Kedrion Biopharma

      9.7.1

      Product Description

      9.7.2

      Regulatory Milestones

      9.7.3

      Safety and Efficacy

      9.8

      IQYMUNE: LFB Biopharmaceuticals

      9.8.1

      Product Description

      9.8.2

      Regulatory Milestones

      9.9

      INTRATECT: Biotest/Grifols

      9.9.1

      Product Description

      9.9.2

      Regulatory Milestones

      9.9.3

      Other Developmental Activities

      9.10

      VENOGLOBULIN: Japan Blood Products Organization

      9.10.1

      Product Description

      9.10.2

      Regulatory Milestones

      9.10.3

      Other Developmental Activities

      9.10.4

      Safety and Efficacy

      9.11

      KENKETSU VENILON: KM Biologics/ Teijin

      9.11.1

      Product Description

      9.11.2

      Regulatory Milestones

      9.11.3

      Other Developmental Activities

      9.11.4

      Safety and Efficacy

      9.12

      Kenketu GLOVENIN-I: Nihon Pharmaceutical/ Takeda

      9.12.1

      Product Description

      9.12.2

      Regulatory Milestones

      9.12.3

      Other Developmental Activities

      9.12.4

      Safety and Efficacy

      9.13

      YIMMUGO: Biotest AG

      9.13.1

      Product Description

      9.13.2

      Regulatory Milestones

      9.13.3

      Other Developmental Activities

      9.13.4

      Clinical Development

      9.13.5

      Safety and Efficacy

      9.14

      ALYGLO: GC Biopharma

      9.14.1

      Product Description

      9.14.2

      Regulatory Milestones

      9.14.3

      Other Developmental Activities

      9.14.4

      Clinical Development

      9.14.5

      Safety and Efficacy

      9.15

      PRIVIGEN: CSL Behring

      9.15.1

      Product Description

      9.15.2

      Regulatory milestones

      9.15.3

      Other Developmental Activities

      9.15.4

      Clinical Development

      9.15.5

      Safety and Efficacy

      9.16

      PANZYGA: Pfizer/Octapharma

      9.16.1

      Product Description

      9.16.2

      Regulatory Milestones

      9.16.3

      Other Developmental Activities

      9.16.4

      Clinical Development

      9.16.5

      Safety and Efficacy

      10

      Emerging Therapies

      10.1

      Key Cross Competition

      10.2

      TAK-880 : Takeda

      10.2.1

      Product Description

      10.2.2

      Other Developmental Activities

      10.2.3

      Analyst View

      11

      IVIG: 7 Major Market Analysis

      11.1

      Key Findings

      11.2

      Market Outlook

      11.3

      Key Market Forecast Assumptions

      11.4

      Market Size of IVIG in the 7MM

      11.5

      The United States

      11.5.1

      Total Market Size of IVIG in the United States

      11.5.2

      Market Size of IVIG by Products in the United States

      11.6

      EU4 and the UK

      11.6.1

      Total Market Size of IVIG in EU4 and the UK

      11.6.2

      Market Size of IVIG by Products in EU4 and the UK

      11.7

      1.5 Japan

      11.7.1

      Total Market Size of IVIG in Japan

      11.7.2

      Market Size of IVIG by Products in Japan

      12

      KOL Views

      13

      SWOT Analysis

      14

      Unmet Needs

      15

      Market Access and Reimbursement

      15.1

      United States

      15.1.1

      Centre for Medicare and Medicaid Services (CMS)

      15.2

      EU4 and the UK

      15.2.1

      Germany

      15.2.2

      France

      15.2.3

      Italy

      15.2.4

      Spain

      15.2.5

      United Kingdom

      15.3

      Japan

      15.3.1

      MHLW

      15.4

      Market Access and Reimbursement in IVIG

      15.4.1

      ASCENIV

      15.4.2

      BIVIGAM

      15.4.3

      PANZYGA

      15.4.4

      PRIVIGEN

      15.4.5

      ALYGLO

      15.4.6

      IQYMUNE

      16

      Appendix

      16.1

      Bibliography

      16.2

      Report Methodology

      17

      DelveInsight Capabilities

      18

      Disclaimer

      Related Reports

      Immune Thrombocytopenia Market

      Immune Thrombocytopenia Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key immune thrombocytopenia companies, including Rigel Pharmaceuticals, Kissei Pharmaceutical, Sobi (Dova Pharmaceuticals), Asahi Kasei Pharma, Amgen, Argenx, Grifols (Biotest), Zenyaku Kogyo, Chugai Pharmaceutical, Novartis, Principia Biopharma, GC Pharma, UCB Biopharma, Takeda (Millennium Pharmaceuticals), Pfizer, Genosco, Oscotec, Vertex, Alpine Immune Sciences, Sanofi, Bioverativ company, among others.

      Guillain-Barre Syndrome Market

      Guillain-Barre Syndrome Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Guillain-Barre syndrome companies, including Annexon, Hansa Biopharma, among others.

      Chronic Inflammatory Demyelinating Polyradiculoneuropathy Market

      Chronic Inflammatory Demyelinating Polyradiculoneuropathy Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CIDP companies, including Sanofi, Novartis, Eli Lilly, Celgene, AbbVie, Takeda Pharmaceuticals, among others.

      Kawasaki Disease Market

      Kawasaki Disease Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key Kawasaki disease companies, including Ampio Pharmaceuticals, Anviron, Reven Pharmaceuticals, among others.

      About DelveInsight

      DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

      Contact Us
      Shruti Thakur
      [email protected]
      +14699457679

      Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

      SOURCE DelveInsight Business Research, LLP

      Modal title

      Also from this source

      Epilepsy Market Set to Grow During the Forecast Period (2026-2036) as Novel Antiseizure Therapies Gain Momentum | DelveInsight

      Epilepsy Market Set to Grow During the Forecast Period (2026-2036) as Novel Antiseizure Therapies Gain Momentum | DelveInsight

      Recently published Epilepsy Market Insights report includes a comprehensive understanding of current treatment practices, epilepsy emerging drugs,...

      JAK Inhibitors Market to Register Notable Growth During the Forecast Period (2026-2036) Through Expanding Clinical and Commercial Landscape | DelveInsight

      JAK Inhibitors Market to Register Notable Growth During the Forecast Period (2026-2036) Through Expanding Clinical and Commercial Landscape | DelveInsight

      DelveInsight's JAK Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding...

      More Releases From This Source

      Explore

      Biotechnology

      Biotechnology

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.